NIMG-26. EVALUATING THE DAYS GAINED RESPONSE METRIC IN CLINICAL TRIALS USING BEVACIZUMAB PLUS ADDITIONAL AGENTS FOR RECURRENT GLIOBLASTOMA

Determining effective therapies for patients with recurrent glioblastoma remains difficult especially in small early phase clinical trials. Currently utilized estimators of treatment response rely on two-dimensional measurements of tumor progression (e.g. RANO, RECIST, MacDonald) that have often fal...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Singleton, Kyle, Johnston, Sandra, Rickertsen, Cassandra, Keith Anderson, S, De Leon, Gustavo, Whitmire, Scott, Clark-Swanson, Kamala, Bendok, Bernard, Mrugala, Maciej, Porter, Alyx, Galanis, Evanthia, Swanson, Kristin
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Neuro-Imaging
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847498/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.697
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares